LAVAL, Quebec, Sept. Oct. 30, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACAST) announced full year 2013-2014 results. (“Acasti” or the “Company”) ACSTACSTa specialty late-stage pharmaceutical company developing three clinical-stage drug candidates for rare and rare diseases, announced today that a U.S. court has dismissed the remaining shareholder lawsuits related to the acquisition of Grace Therapeutics, Inc. by the companies have been submitted.Gracefulness“) by merger in August 2021 (the “mergerAs previously announced, four lawsuits have been filed by shareholders against Acasti and certain of its directors and officers in connection with the merger, alleging that the company’s public disclosures related to the merger misstate or misrepresent material information omitted and violated Section 14(a) of the US Securities Exchange Act of 1934. Two of the four cases were voluntarily dismissed, and the remaining two cases were consolidated before Judge Katherine Polk Failla of the United States District Court for the Southern District of New York, Acasti and the individual defendants filed a motion to dismiss on February 25, 2022. In a 45-page opinion released earlier today, Judge Failla granted the motion to dismiss in its entirety, noting that the consolidated complaint did not allege any facts , which showed that Acasti is a materially misleading statement or material omission in its merger-related disclosures. Accordingly, subject to any remedies available in response to today’s judgment, all fo Our merger-related actions by shareholders have now been dismissed.

About Acasti

Acasti is a late-stage specialty pharmaceutical company developing three clinical-stage drug candidates for rare and orphan diseases. Acasti’s novel drug delivery technologies have the potential to improve the performance of drugs currently on the market by providing faster onset of action, improved efficacy, fewer side effects and more convenient drug delivery – all of which could help increase therapy adherence and improve patient outcomes.

Acastis…